Comparative Pharmacology
Head-to-head clinical analysis: METOCURINE IODIDE versus MIVACRON IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOCURINE IODIDE versus MIVACRON IN DEXTROSE 5 IN PLASTIC CONTAINER.
METOCURINE IODIDE vs MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive nicotinic acetylcholine receptor antagonist at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine-mediated depolarization and muscle contraction.
Initial dose 0.2 mg/kg IV; maintenance doses of 0.1-0.15 mg/kg IV as needed for neuromuscular blockade.
Initial IV bolus of 0.15-0.2 mg/kg (following succinylcholine) or 0.25 mg/kg (without succinylcholine) over 30-60 seconds. Maintenance infusion: 8-10 mcg/kg/min for continuous neuromuscular blockade during anesthesia.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in patients with normal renal function. Prolonged in renal impairment.
Terminal elimination half-life is approximately 2-3 minutes (0.03-0.05 h) due to rapid hydrolysis by plasma esterases; clinical duration is short, with recovery of neuromuscular function beginning within 5-10 minutes after bolus dose.
Renal: 85-90% unchanged; biliary/fecal: <5%.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of the dose; biliary/fecal elimination accounts for the remainder, primarily as metabolites via the liver.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker